Clinical Research in Cardiology

, Volume 97, Issue 10, pp 773–781 | Cite as

Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter

  • Bruno Scheller
  • Christoph Hehrlein
  • Wolfgang Bocksch
  • Wolfgang Rutsch
  • Dariush Haghi
  • Ulrich Dietz
  • Michael Böhm
  • Ulrich Speck



We are presenting an extension of a previously published trial on the efficacy and safety of a paclitaxel-coated balloon in coronary ISR in a larger patient population and after a complete follow-up of 2 years.


Hundred eight patients were enrolled in two separately randomized, double-blind multicenter trials on efficacy and safety using an identical protocol. Patients were treated by the paclitaxel-coated (3 µg/mm2 balloon surface; Paccocath) or an uncoated balloon. The main inclusion criteria were a diameter stenosis of ≥70% and <30 mm length with a vessel diameter of 2.5–3.5 mm. The primary endpoint was angiographic late lumen loss in-segment. Secondary endpoints included binary restenosis rate and major adverse cardiovascular events (MACE).


Quantitative coronary angiography revealed no differences in baseline parameters. After six months in-segment late lumen loss was 0.81 ± 0.79 mm in the uncoated balloon group vs. 0.11 ± 0.45 mm (P < 0.001) in the drug-coated balloon group resulting in a binary restenosis rate of 25/49 vs. 3/47 (P < 0.001). Until 12 months post procedure 20 patients in the uncoated balloon group compared to two patients in the coated balloon group required target lesion revascularization (P = 0.001). Between 12 and 24 only two MACE were recorded, a stroke in the uncoated and a target lesion revascularization in the coated balloon group.


Treatment of coronary ISR with paclitaxel-coated balloon catheters persistently reduces repeat restenosis up to 2 years. ( Identifier: NCT00106587, NCT00409981).


paccocath drug-coated balloon in-stent restenosis 



The authors thank Matthias Braeutigam, MD, Schering AG Berlin, for supporting basic experiments leading to the clinical studies. The authors further thank Wolfgang Gimbel, MD for clinical monitoring, Bettina Kelsch for critical data review and report writing, Bianca Werner and Nicole Hollinger for handling the database, and Kevin Wilhelmi for assistance in quantitative analysis of coronary angiographies. Statistical analysis was supported by BIAS GmbH, Berlin, Germany.

Disclosures: The study was supported by Bavaria Medizintechnik GmbH, Oberpfaffenhoven and Bayer-Schering Pharma AG, Berlin, both Germany. Dr. Scheller and Dr. Speck report being co-inventors of a patent application for various methods of restenosis inhibition, including the technique employed in this trial, by Charité University Hospital, Berlin. Dr. Speck reports serving as a consultant to Bayer-Schering AG, Berlin.


  1. 1.
    Alfonso F, Perez-Vizcayno MJ, Hernandez R, Bethencourt A, Marti V, Lopez-Minguez JR, Angel J, Mantilla R, Moris C, Cequier A, Sabate M, Escaned J, Moreno R, Banuelos C, Suarez A, Macaya C, RIBS-II Investigators (2006) A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the restenosis intrastent: balloon angioplasty Vs. elective sirolimus-eluting stenting (RIBS-II) trial. J Am Coll Cardiol 47:2152–2160PubMedCrossRefGoogle Scholar
  2. 2.
    Camenzind E, Steg PG, Wijns W (2007) Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115:1440–1455; discussion 1455, Epub 2007 Mar 7PubMedCrossRefGoogle Scholar
  3. 3.
    Carlsson J, von Wagenheim B, Linder R, Anwari TM, Qvist J, Petersson I, Magounakis T, Lagerqvist B (2007) Is late stent thrombosis in drug-eluting stents a real clinical issue?: a single-center experience and review of the literature. Clin Res Cardiol 96:86–93PubMedCrossRefGoogle Scholar
  4. 4.
    Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC, Llanos G, Dooley J, Falotico R (2004) Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 63:617–624PubMedCrossRefGoogle Scholar
  5. 5.
    Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369:667–678PubMedCrossRefGoogle Scholar
  6. 6.
    Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, Scott DS, Froehlich J, Virmani R (2001) Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104:473–479PubMedCrossRefGoogle Scholar
  7. 7.
    Herdeg C, Oberhoff M, Baumbach A, Blattner A, Axel DI, Schroder S, Heinle H, Karsch KR (2000) Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 35:1969–1976PubMedCrossRefGoogle Scholar
  8. 8.
    Holmes DR Jr, Teirstein P, Satler L, Sketch M, O’Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA, SISR Investigators (2006) Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA 295:1264–1273; Epub 2006 Mar 12PubMedCrossRefGoogle Scholar
  9. 9.
    Hwang CW, Wu D, Edelman ER (2001) Physiological transport forces govern drug distribution for stent-based delivery. Circulation 104:600–605PubMedCrossRefGoogle Scholar
  10. 10.
    Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130PubMedCrossRefGoogle Scholar
  11. 11.
    ICH Harmonized Tripartite Guideline. Clinical safety data management: definitions and standards for expedited reporting E2A. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. October 1994. Available on-line at /LOB/media/MEDIA436.pdf. Accessed 23 Jun 2006
  12. 12.
    Iofina E, Haager PK, Radke PW, Langenberg R, Blindt R, Ortlepp J, Kuhl H, Hanrath P, Hoffmann R (2005) Sirolimus- and paclitaxel-eluting stents in comparison with balloon angioplasty for treatment of in-stent restenosis. Catheter Cardiovasc Interv 64:28–34PubMedCrossRefGoogle Scholar
  13. 13.
    Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193–202PubMedCrossRefGoogle Scholar
  14. 14.
    Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schuhlen H, Schmitt C, Dirschinger J, Schomig A, ISAR-DESIRE Study Investigators (2005) Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293:165–171PubMedCrossRefGoogle Scholar
  15. 15.
    Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schomig A (2007) Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:1030–1039; Epub 2007 Feb 12PubMedCrossRefGoogle Scholar
  16. 16.
    Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L, SCAAR Study Group (2007) Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356:1009–1019; Epub 2007 Feb 12PubMedCrossRefGoogle Scholar
  17. 17.
    Maisel WH (2007) Unanswered questions–drug-eluting stents and the risk of late thrombosis. N Engl J Med 356:981–984PubMedCrossRefGoogle Scholar
  18. 18.
    Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356:1020–1029; Epub 2007 Feb 12PubMedCrossRefGoogle Scholar
  19. 19.
    Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB (1999) Angiographic patterns of in-stent restenosis: classification and implications for long term outcome. Circulation 100:1872–1878PubMedGoogle Scholar
  20. 20.
    Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R, RAVEL Study Group (2002) Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de Novo Native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773–1780PubMedCrossRefGoogle Scholar
  21. 21.
    Nordmann AJ, Briel M, Bucher HC (2006) Mortality in randomized controlled trials comparing drug-eluting Vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27:2784–814; Epub 2006 Oct 4PubMedCrossRefGoogle Scholar
  22. 22.
    Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C, BASKET-LATE Investigators (2006) Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48:2584–2591; Epub 2006 Nov 2PubMedCrossRefGoogle Scholar
  23. 23.
    Scheller B, Grandt A, Wnendt S, Kuttler B, Bolz U, Lorenz G, Böhm M, Nickenig G (2005) Comparative study of tacrolimus and paclitaxel stent coating to prevent restenosis after coronary intervention. Z Kardiol 94:445–452PubMedCrossRefGoogle Scholar
  24. 24.
    Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U (2006) Treatment of in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 355:2113–2124PubMedCrossRefGoogle Scholar
  25. 25.
    Scheller B, Kühler M, Cremers B, Mahnkopf D, Böhm M, Boxberger M (2008) Short- and long-term effects of a novel paclitaxel coated stent in the porcine coronary model. Clin Res Cardiol 97:118–123PubMedCrossRefGoogle Scholar
  26. 26.
    Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G (2004) Paclitaxel balloon coating—a novel method for prevention and therapy of restenosis. Circulation 110:810–814PubMedCrossRefGoogle Scholar
  27. 27.
    Scheller B, Speck U, Böhm M (2007) Prevention of restenosis—is angioplasty the answer? Heart 93:539–541PubMedCrossRefGoogle Scholar
  28. 28.
    Scheller B, Speck U, Romeike B, Schmitt A, Sovak M, Böhm M, Stoll HP (2003) Contrast media as a carrier for local drug delivery: successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 24(15):1462–1467PubMedCrossRefGoogle Scholar
  29. 29.
    Scheller B, Speck U, Schmitt A, Böhm M, Nickenig G (2003) Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 42(8):1415–1420PubMedCrossRefGoogle Scholar
  30. 30.
    Silber S, Popma JJ, Suntharalingam M, Lansky AJ, Heuser RR, Speiser B, Teirstein PS, Bass T, O’Neill W, Lasala J, Reisman M, Sharma SK, Kuntz RE, Bonan R (2005) Two-year clinical follow-up of 90Sr/90Y beta-radiation versus placebo control for the treatment of instent restenosis (START). Am Heart J 149:689–694PubMedCrossRefGoogle Scholar
  31. 31.
    Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:989–997; Epub 2007 Feb 12PubMedCrossRefGoogle Scholar
  32. 32.
    Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Böhm M, Hamm B (2006) Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology 240:411–418PubMedCrossRefGoogle Scholar
  33. 33.
    Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB (2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356:998–1008; Epub 2007 Feb 12PubMedCrossRefGoogle Scholar
  34. 34.
    Stone GW, Ellis SG, O’Shaughnessy CD, Martin SL, Satler L, McGarry T, Turco MA, Kereiakes DJ, Kelley L, Popma JJ, Russell ME, TAXUS V ISR Investigators (2006) Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 295:1253–1263PubMedCrossRefGoogle Scholar
  35. 35.
    Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U (2008) Local taxane with short exposure for reduction of restenosis in distal arteries: thunder trial. N Engl J Med 358:689–699PubMedCrossRefGoogle Scholar
  36. 36.
    van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr, Ellis SG, Topol EJ (1996) Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94:1690–1697PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Bruno Scheller
    • 1
  • Christoph Hehrlein
    • 2
  • Wolfgang Bocksch
    • 3
  • Wolfgang Rutsch
    • 4
  • Dariush Haghi
    • 5
  • Ulrich Dietz
    • 6
  • Michael Böhm
    • 1
  • Ulrich Speck
    • 7
  1. 1.Klinik für Innere Medizin IIIUniversitätsklinikum des SaarlandesHomburgGermany
  2. 2.Klinik für Innere Medizin IIIUniversitätsklinikumFreiburgGermany
  3. 3.Medizinische Klinik mit Schwerpunkt KardiologieUniversitätsklinikum CharitéBerlinGermany
  4. 4.Medizinische Klinik und Poliklinik mit Schwerpunkt Kardiologie, Angiologie, PulmonologieCharité-Universitätsmedizin BerlinBerlinGermany
  5. 5.I. Medizinische KlinikUniversitätsklinikum Mannheim, Ruprecht-Karls-Universität HeidelbergMannheimGermany
  6. 6.KardiologieDeutsche Klinik für DiagnostikWiesbadenGermany
  7. 7.Institut für RadiologieCharité-Universitätsmedizin BerlinBerlinGermany

Personalised recommendations